Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 15 de 15
1.
BMC Pediatr ; 24(1): 382, 2024 Jun 03.
Article En | MEDLINE | ID: mdl-38831258

BACKGROUND: Osteosarcoma is the most common primary malignant bone tumour in children and adolescents. Lungs are the most frequent and often the only site of metastatic disease. The presence of pulmonary metastases is a significant unfavourable prognostic factor. Thoracotomy is strongly recommended in these patients, while computed tomography (CT) remains the gold imaging standard. The purpose of our study was to create tools for the CT-based qualification for thoracotomy in osteosarcoma patients in order to reduce the rate of useless thoracotomies. METHODS: Sixty-four osteosarcoma paediatric patients suspected of lung metastases on CT and their first-time thoracotomies (n = 100) were included in this retrospective analysis. All CT scans were analysed using a compartmental evaluation method based on the number and size of nodules. Calcification and location of lung lesions were also analysed. Inter-observer reliability between two experienced radiologists was assessed. The CT findings were then correlated with the histopathological results of thoracotomies. Various multivariate predictive models (logistic regression, classification tree and random forest) were built and predictors of lung metastases were identified. RESULTS: All applied models proved that calcified nodules on the preoperative CT scan best predict the presence of pulmonary metastases. The rating of the operated lung on the preoperative CT scan, dependent on the number and size of nodules, and the total number of nodules on this scan were also found to be important predictors. All three models achieved a relatively high sensitivity (72-92%), positive predictive value (81-90%) and accuracy (74-79%). The positive predictive value of each model was higher than of the qualification for thoracotomy performed at the time of treatment. Inter-observer reliability was at least substantial for qualitative variables and excellent for quantitative variables. CONCLUSIONS: The multivariate models built and tested in our study may be useful in the qualification of osteosarcoma patients for metastasectomy through thoracotomy and may contribute to reducing the rate of unnecessary invasive procedures in the future.


Bone Neoplasms , Lung Neoplasms , Osteosarcoma , Thoracotomy , Tomography, X-Ray Computed , Humans , Osteosarcoma/diagnostic imaging , Osteosarcoma/surgery , Osteosarcoma/secondary , Osteosarcoma/pathology , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/surgery , Lung Neoplasms/secondary , Lung Neoplasms/pathology , Adolescent , Child , Retrospective Studies , Male , Female , Bone Neoplasms/secondary , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/surgery
2.
Diagnostics (Basel) ; 12(8)2022 Aug 04.
Article En | MEDLINE | ID: mdl-36010245

(1) Background: The aim of the present study was to assess the cancer stem cell (CSC) markers CD24, CD44, CD133, and ALDH1A1 in rhabdomyosarcoma (RMS) in children and to define their prognostic role in this group of patients. (2) Methods: The study material was archival tissue specimens collected from 49 patients under 18 years of age and who had been diagnosed with RMS. Immunohistochemistry (IHC) was used to evaluate the expression of the selected CSC markers in the tumor tissue. Expression was evaluated using a semiquantitative IRS scale based on the one developed by Remmele and Stenger and was correlated with the clinical and pathomorphological parameters of prognostic importance in RMS. (3) Results: Expression of the selected CSC markers CD24, CD44, CD133, and ALDH1A1 was demonstrated in 83.7%, 55.1%, 81.6%, and 100% of the RMS patients, respectively. The expression of all of the assessed CSC markers was statistically significantly higher in the study group versus the control group. No significant correlation was found between the expression of the selected CSC markers and clinical and pathological prognostic factors that were analyzed. The expression of the CSC markers did not have a significant influence on RMS survival rates. (4) Conclusions: The results of the conducted study confirm the expression of selected CSC markers in rhabdomyosarcoma tissue in children. The study did not support the prognostic relevance of the expression of any of the assessed CSC markers. However, further studies are needed to fully understand the relevance of the selected CSC markers in RMS carcinogenesis.

3.
J Clin Med ; 11(6)2022 Mar 17.
Article En | MEDLINE | ID: mdl-35329989

Aims. There are no data on the redox status of children with bone tumors in complete disease remission. Therefore, the presented study examined the reduced/oxidized glutathione (GSH/GSSG) ratio, total oxidant capacity (TOC) and total antioxidant capacity (TAC) values as well as the oxidative stress index (OSI) for assessing alterations in the oxidant/antioxidant balance in 35 children with osteosarcoma or Ewing's sarcoma after anticancer therapy completion (median 14 months) compared with a control group. Methods. GSH, GSSG, TOC, TAC concentrations and bone alkaline phosphatase (BALP) activity were evaluated by immunoenzymatic (ELISA) and enzymatic methods. Results. We found no differences in serum BALP activity between all survivors with bone tumors and the control group. Patients with osteosarcoma after anticancer therapy completion had significantly higher values of TAC, GSH and the GSH/GSSG ratio as well as GSSG than healthy subjects. In patients with Ewing's sarcoma, we found significantly higher values of TOC concentration compared with healthy children. In addition, survivors with Ewing's sarcoma had higher TOC concentrations and OSI index values (p < 0.01), but a lower GSH/GSSG ratio (p < 0.05) than survivors with osteosarcoma. A positive correlation between TOC and the post-therapy period was observed in survivors. Conclusions. We found that in survivors with bone tumors, a disturbed balance between prooxidants and antioxidants persists after the completion of anticancer treatment. Moreover, an increased TOC value together with the post-therapy period may suggest increasing oxidative processes in survivors with bone tumors after treatment. Further observations will allow assessment of the relationship between the oxidant/antioxidant status and the predisposition of survivors to bone neoplastic disease recurrence.

4.
J Clin Med ; 10(3)2021 Feb 01.
Article En | MEDLINE | ID: mdl-33535525

(1) Background: The study proposed to analyze microvessel density (MVD) in rhabdomyosarcoma (RMS) based on the expression of angiogenesis markers and define its prognostic role in this group of patients. (2) Methods: The study included forty-nine pediatric patients diagnosed with RMS. Tumor tissue expression of CD31, CD34, and CD105 was analyzed. MVD was calculated and correlated with clinical RMS prognostic parameters. (3) Results: CD31, CD34, and CD105 are expressed in all RMS cases. MVD/CD105 was significantly higher in the RMS group than in the control group. The mean and median values of MVD/CD105 in RMS were lower than MVD/CD31 and MVD/CD34. MVD/CD105 was significantly higher in patients with alveolar RMS and those with metastatic disease. Patients with higher levels of MVD/CD105 had a higher risk of death (HR = 1.009). (4) Conclusion: CD105 is a relevant angiogenesis marker in pediatric RMS, and MVD/CD105 is an independent risk factor of short overall survival in children with RMS.

5.
Pediatrics ; 142(3)2018 09.
Article En | MEDLINE | ID: mdl-30082451

BACKGROUND AND OBJECTIVES: There is no consensus on optimal treatment duration for propranolol in infantile hemangioma (IH). We evaluated the efficacy and safety of oral propranolol solution administered for a minimum of 6 months up to a maximum of 12 months of age in high-risk IH. METHODS: This single-arm, open-label, phase 3 study was conducted in patients aged 35 to 150 days with high-risk IH in 10 hospitals between 2015 and 2017. The study comprised a 6-month initial treatment period (ITP) plus continuation up to 12 months of age if complete success was not achieved, a follow-up, and a retreatment period. Patients received oral propranolol twice daily (3 mg/kg per day). The primary end point was the success rate at the end of the ITP. Furthermore, the persistence of IH response and efficacy of retreatment was evaluated. RESULTS: The success rate after 6 months of treatment was 47%, increasing to 76% at the end of the ITP. Of the patients who achieved success, 68% sustained success for 3 months without treatment, and 24% required retreatment. Of the 8 patients who were retreated, 7 achieved success. Adverse events, reported by 80% of patients, were mild, which were expected in this population or known propranolol side effects. CONCLUSIONS: Oral propranolol administered beyond 6 months and up to 12 months of age meaningfully increases the success rate in high-risk IH. Success was sustained in most patients up to 3 months after stopping treatment. Retreatment was efficacious, and the safety profile satisfactory.


Adrenergic beta-Antagonists/administration & dosage , Hemangioma/diagnosis , Hemangioma/drug therapy , Propranolol/administration & dosage , Administration, Oral , Drug Administration Schedule , Female , Humans , Infant , Male , Risk Factors , Treatment Outcome
6.
Dev Period Med ; 22(1): 58-64, 2018.
Article En | MEDLINE | ID: mdl-29641422

OBJECTIVE: Aim: The aim of this study was to assess the usefulness of bone-specific alkaline phosphatase (BALP) and the extracelluar domain of human epidermal growth factor receptor 2 (ECD/HER-2) measurements in pediatric patients with osteosarcoma as prospective prognostic and predictive markers for monitoring the treatment and early detection of disease recurrence. PATIENTS AND METHODS: Material and methods: We studied 22 patients (5 girls, 17 boys) aged 7-20 years with osteosarcoma (OS) treated at the Institute of Mother and Child in Warsaw. All the patients were evaluated for the serum levels of BALP and ECD/HER-2 before treatment, during pre- and postoperative chemotherapy and after the completion of treatment. Healthy children (n=22) were the reference group. The levels of BALP and ECD/HER-2 were measured using immunoenzymatic methods. RESULTS: Results: The values of BALP and ECD/HER-2 proteins were higher (p<0.01; p<0.05, respectively) in patients with osteosarcoma at the time of diagnosis compared with the control group. The values of both markers significantly decreased during chemotherapy in most patients with remission. In contrast to ECD/HER-2, the value of BALP after therapy was higher in patients with progression than with remission (p<0.001). CONCLUSION: Conclusions: Our results demonstrate the different pattern of BALP and ECD/HER-2 proteins during clinical treatment in patients with osteosarcoma. Higher values of BALP may characterize the progression of the disease and unfavourable prognosis. Further longitudinal studies are necessary to confirm the prognostic values of BALP and ECD/HER-2 proteins in this group of patients.


Alkaline Phosphatase/blood , Bone Neoplasms/blood , Osteosarcoma/blood , Receptor, ErbB-2/blood , Adolescent , Bone Neoplasms/drug therapy , Bone Neoplasms/surgery , Child , Female , Humans , Male , Osteosarcoma/drug therapy , Osteosarcoma/surgery , Perioperative Period , Prognosis , Young Adult
7.
J Cancer Res Clin Oncol ; 144(3): 519-529, 2018 Mar.
Article En | MEDLINE | ID: mdl-29332262

PURPOSE: Selected cell-cycle regulators and extracellular matrix proteins were found to play roles in malignant peripheral nerve sheath tumor (MPNST) biology. We aimed to analyze whether initial tumor tissue expressions of survivin, p53, cyclin D1, osteopontin (OPN) and fibronectin (FN) correlate with the response to neo-adjuvant CHT (naCHT) in children with advanced inoperable MPNST. METHODS: The study included 26 children with MPNST (M/F 14/12, median age 130 months) treated in Polish centers of pediatric oncology between 1992 and 2013. Tissue expression of markers was studied immunohistochemically in the manually performed tissue microarrays and assessed semi-quantitatively as low and high, based on the rate of positive cells and staining intensity. RESULTS: Good response to naCHT was noted in 47.6%, while poor-in 52.4% of patients. The response to naCHT was influenced negatively by the presence of neurofibromatosis NF1 and high initial tumor tissue expression of OPN, survivin, p53 and cyclin D1. Patients with high tumor expression of either OPN, survivin or p53 and those with simultaneous high expression of ≥ 3 of the markers, responded significantly worse to naCHT, than patients, in whom expression of ≤ 2 markers were detected at diagnosis. Nearly, 85% of patients expressing ≥ 3 markers, responded poor to CHT; while 87.5% of children, expressing ≤ 2 markers, were good responders. CONCLUSION: The initial tumor tissue expression of OPN, survivin, p53 and cyclin D1 may serve as markers to predict response to naCHT in pediatric advanced MPNST. Future studies in more numerous group of patients are needed to confirm these preliminary results.


Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/metabolism , Cyclin D1/metabolism , Cytokines/metabolism , Inhibitor of Apoptosis Proteins/metabolism , Nerve Sheath Neoplasms/diagnosis , Nerve Sheath Neoplasms/drug therapy , Osteopontin/metabolism , Adolescent , Biomarkers, Pharmacological/metabolism , Child , Child, Preschool , Disease Progression , Female , Fibronectins , Humans , Infant , Male , Neoadjuvant Therapy , Nerve Sheath Neoplasms/metabolism , Nerve Sheath Neoplasms/pathology , Neurilemmoma/drug therapy , Neurilemmoma/metabolism , Neurilemmoma/pathology , Prognosis , Survivin , Treatment Outcome
8.
Pediatr Neonatol ; 57(4): 295-301, 2016 08.
Article En | MEDLINE | ID: mdl-26934827

BACKGROUND: Advances in multidisciplinary care for pediatric cancer have resulted in significant improvement in cure rates over the last decades; however, these advances have not been uniform across all age groups. Cancer is an important cause of perinatal mortality, yet the full spectrum of malignant neoplasms in newborns is not well defined. METHODS: The authors have reviewed the clinical features and outcomes of 37 newborns with congenital malignant tumors treated at three referral centers in North, Central, and South Poland between 1980 and 2014. Event-free survival (EFS) and overall survival (OS) rates were estimated by Kaplan-Meier methods and compared using long-rank test and Cox models. RESULTS: Twenty-two patients were diagnosed prenatally. The most common diagnoses were neuroblastoma (48.7%), followed by malignant germ-cell tumor (16.2%), and Wilms' tumor (8.1%). Neuroblastoma was the most common malignancy among full-term infants, and malignant sacrococcygeal teratoma was the most common malignancy in premature infants. Thirty patients (81%) are alive with a median follow-up of 4.8 years from diagnosis. Patients with Wilms' tumor and malignant germ-cell tumors had the best outcomes (5-year OS 100% for both), whereas the worst prognosis was observed for sarcoma patients (5-year OS 72.92%). Premature infants had better outcome than full-term infants (5-year OS 92.8% vs. 72.58%, respectively). CONCLUSION: Although rare, neonatal cancers can present with an aggressive clinical behavior, but they have a generally good outcome. Early diagnosis and management by expert multidisciplinary teams that integrate perinatal medicine experts with pediatric and surgical oncologists are critical. Centralized care with clear referral pathways that facilitate early initiation of specialized treatment should be prioritized.


Neoplasms, Germ Cell and Embryonal/mortality , Neoplasms, Germ Cell and Embryonal/pathology , Disease-Free Survival , Female , Humans , Infant, Newborn , Infant, Premature , Infant, Premature, Diseases/mortality , Infant, Premature, Diseases/pathology , Male , Poland/epidemiology , Referral and Consultation , Retrospective Studies , Survival Rate
9.
J Pediatr Surg ; 51(7): 1067-71, 2016 Jul.
Article En | MEDLINE | ID: mdl-26707423

BACKGROUND: Ewing sarcoma (ES) is the second most common pediatric malignant bone tumor with a wide spectrum of clinical presentations. Although metastatic disease to the lungs is often the cause of death, isolated lung metastases at diagnosis are not frequent. The specific role of chemotherapy, surgery, and lung radiation has not been clearly defined. We investigated prognostic factors and the impact of the different treatment modalities in a cohort of patients with ES with isolated lung metastases. MATERIALS AND METHODS: Thirty-eight patients with ES and isolated lung metastases were treated using modern multimodal therapy during the period 2000-2014. According to the imaging characteristics of lung nodules patients were allocated into one of four treatment groups: "0" without nodules, "1" one solitary nodule of <0.5cm or several nodules of <0.3cm, "2" solitary nodule of 0.5-1cm or multiple nodules of 0.3-0.5cm, "3" one pulmonary/pleural nodule of >1cm, or more than one nodule of >0.5cm. Factors predictive of outcome were analyzed. Overall survival was estimated by Kaplan-Meier methods and compared using long-rank test and Cox models. RESULTS: Treatment of the lung metastases was performed in 23 cases (60.5%): twenty patients underwent lung surgery, 6 of them received additional postoperative whole lung radiation; three patients received lung radiation only. Malignant cells were found in all lung nodules of patients from group "3", in 5 (62.5%) patients from group "2", and none of the group "1". There was a correlation between histological response of the primary tumor and outcome. Three-year estimates of EFS and OS were 45.19% and 60.7%, respectively. Patients with good response measured by chest CT had significantly better EFS than patients with poor response (81% vs. 27.66%, respectively, p=0.006). CONCLUSIONS: Metastatectomy may have a role in the treatment of highly selected patients with ES and isolated lung metastases depending on the histologic response to therapy. Further studies are needed to better define the use of surgery and the response-adapted criteria in the upfront management of this population.


Bone Neoplasms/pathology , Lung Neoplasms/secondary , Sarcoma, Ewing/secondary , Adolescent , Child , Combined Modality Therapy/methods , Disease Management , Female , Follow-Up Studies , Humans , Male , Proportional Hazards Models , Retrospective Studies , Sarcoma, Ewing/therapy
10.
Klin Oczna ; 117(2): 101-3, 2015.
Article En | MEDLINE | ID: mdl-26638547

We describe the case of a 16-month-old girl with neuroblastoma and chronic lymphocytopenia due to chemotherapy and treosulfan-containing megatherapy who developed cytomegalovirus retinitis and neuritis. Intravenous ganciclovir and anti-cytomegalovirus immunoglobulin were used with a transient benefit; however, retrobulbar gancyclovir resulted in a complete remission. This report emphasizes the need for close monitoring of viral infections in patients undergoing treosulfan-containing megatherapy, highlighting the immunosuppressive effects of this agent, and indicates the potential use of retrobulbar ganciclovir as the alternative method of drug delivery.


Antiviral Agents/administration & dosage , Cytomegalovirus Infections/drug therapy , Cytomegalovirus Infections/etiology , Ganciclovir/administration & dosage , Retinitis/drug therapy , Retinitis/etiology , Antineoplastic Agents, Alkylating/adverse effects , Bone Marrow Transplantation/adverse effects , Busulfan/adverse effects , Busulfan/analogs & derivatives , Female , Humans , Infant , Leukemia/complications , Leukemia/therapy , Treatment Outcome
11.
Pediatr Blood Cancer ; 62(6): 988-93, 2015 Jun.
Article En | MEDLINE | ID: mdl-25557806

BACKGROUND: Recent data support the concept that adipokines, which are secreted by fat cells, are important modulators of bone metabolism. The aim of this study was to assess the relationships between body composition parameters, adipokines (leptin, adiponectin) and bone mineral density (BMD) in patients with malignant bone tumors after anticancer therapy. PROCEDURE: The study included 35 patients (median age 14.8 years) with diagnosed malignant bone tumors treated according to obligatory protocols. Total fat mass, lean mass, bone mineral content (BMC) and BMD measurements were performed after treatment completion by dual energy-ray absorptiometry (DXA). Serum concentrations of leptin, leptin receptor and adiponectin were determined using immunoenzymatic assays. The control group consisted of 28 healthy children (median age 14.3 years). RESULTS: Patients with bone tumor after chemotherapy had significantly higher fat mass (P < 0.01), increased ratio of fat mass/lean mass (P < 0.001), and a decrease (P < 0.001) in total body and lumbar spine BMD compared with controls. We observed higher serum leptin concentration (P < 0.01) and lower soluble leptin receptor (P < 0.001) and adiponectin (P = 0.01) in patients than in controls. The ratios of leptin/leptin receptor and leptin/adiponectin were about three-fold higher in patients compared with the control group (P = 0.001). We found a significant positive correlation between BMD and body composition and a negative correlation between BMD and adiponectin in the patients group. CONCLUSIONS: Changes in body composition parameters coexisting with disturbed adipokine levels, especially higher levels of leptin and lower levels of adiponectin, might be associated with bone status in patients treated for malignant bone tumors.


Adipokines/blood , Body Composition , Bone Density , Bone Neoplasms/metabolism , Adolescent , Adult , Body Mass Index , Child , Female , Humans , Leptin/blood , Male , Sex Characteristics
12.
J Pediatr Surg ; 49(10): 1500-4, 2014 Oct.
Article En | MEDLINE | ID: mdl-25280655

BACKGROUND: Pelvic Ewing sarcoma (ES) is commonly associated with a worse prognosis. Large size and location limit local control options to radiation therapy, and local recurrences are common. We evaluated the impact of hemipelvectomy and radiation on outcomes, including function. MATERIALS AND METHODS: Thirty-nine patients (median age 13.5years) with ES of the pelvis and sacral bones were treated during the period 2000-2012. Fifteen were treated with definitive radiotherapy (RT), 9 patients underwent hemipelvectomy alone, and 15 were treated with combined hemipelvectomy and RT. RESULTS: Twenty patients (51.2%) are alive with a median follow-up 3.2years from diagnosis. Median time from diagnosis to relapse was 1.3years. Three-year estimates of EFS and OS were 47% and 61%, respectively. Patients treated with surgery or surgery with RT had better outcome than patients treated with RT only (3-year OS 78% or 81% vs. 36%, respectively, p=0.00083). The outcome of patients with pelvic ES treated with hemipelvectomy was not significantly different from the outcome of all patients with Ewing sarcoma treated on the national Polish protocol. CONCLUSIONS: Internal hemipelvectomy offers good chances of cure for patients with pelvic ES, with a reasonable rate of complications and good function.


Bone Neoplasms/surgery , Hemipelvectomy/methods , Sarcoma, Ewing/surgery , Adolescent , Bone Neoplasms/radiotherapy , Child , Child, Preschool , Combined Modality Therapy , Humans , Neoplasm Recurrence, Local , Pelvic Bones/surgery , Sacrum/surgery , Sarcoma, Ewing/radiotherapy , Treatment Outcome , Young Adult
13.
Pol Merkur Lekarski ; 37(218): 86-90, 2014 Aug.
Article Pl | MEDLINE | ID: mdl-25252441

UNLABELLED: Cancer and the use of a comprehensive anti-cancer treatment are unfavorable factors, which have a significant impact on bone mass accumulation, bone mineralization and consequently the occurrence of osteoporosis. Bone turnover is regulated by complex mechanisms, among which an important role play OPG/RANK/RANKL signaling pathway, adipokines, and fetuin-A. The aim of the study was to evaluate bone mineral density and concentrations of leptin and fetuin-A in patients with osteosarcoma after anti-cancer treatment. MATERIALS AND METHODS: The study included 50 children and adolescents aged 10-21 years. The study group consisted of 25 patients with osteosarcoma and 25 healthy counterparts as a control group. The examination was conducted 2 months after the last course of postoperative chemotherapy and included densitometric measurements: bone mineral content (BMC), bone mineral density (BMD), fat mass, lean mass and biochemical measurements: serum concentrations of calcium, magnesium, phosphate, 25-hydroksyvitamin D, alkaline phosphatase, leptin and fetuin-A. Concentrations of leptin and fetuin-A were determined by immunoenzymatic methods. RESULTS: In patients with osteosarcoma after anti-cancer treatment, we observed significantly reduced bone mineral content, bone mineral density and lean body mass compared with the healthy children (p < 0.05, p < 0.01, p < 0.05, respectively). Mean values of z-score of the whole body BMD and z-score of the lumbar BMD L1-L4 were significantly lower in patients than in the controls (p < 0.001). The serum concentrations of phosphate, magnesium, and alkaline phosphatase in both studied groups were similar, while calcium was significantly lower (p < 0.05) in patients than in the healthy children. The concentration of 25-hydroxyvitamin D was about two-fold lower, while leptin approximately 2.5-fold higher in patients than in the controls. The mean value of fetuin-A was similar in both studied groups. Statistically significant positive correlations between body composition parameters and the values of BMD, as well as between anthropometric parameters and leptin and fetuin-A were observed. CONCLUSION: The deficit in bone mass observed in patients with malignant bone tumors after anti-cancer treatment might be the result of decreased serum calcium and vitamin D concentrations. The observed correlation between anthropometric and biochemical parameters may indicate the link between bone and adipose tissue metabolism.


Anthropometry , Bone Neoplasms/metabolism , Bone Neoplasms/therapy , Leptin/blood , Osteosarcoma/metabolism , Osteosarcoma/therapy , alpha-2-HS-Glycoprotein/metabolism , Adipose Tissue/metabolism , Adolescent , Adult , Alkaline Phosphatase/blood , Bone Density , Bone and Bones/metabolism , Calcium/blood , Child , Female , Humans , Magnesium/blood , Male , Vitamin D/analogs & derivatives , Vitamin D/blood , Young Adult
14.
Przegl Lek ; 61 Suppl 2: 24-8, 2004.
Article Pl | MEDLINE | ID: mdl-15686042

UNLABELLED: In the Institute of Mother and Child in Warsaw, in the years 1985-2002, 382 osteosarcoma patients were treated. The ages of the patients were from 3 to 26 years old. 117 patients had metastases. The whole group of patients was divided into two groups. Treatment was begun from chemotherapy. When stabilization or partial regression was observed the operative procedures was made. In progression conservative treatment was used. RESULTS: In the group of 18 patients for whose was used conservative treatment only, 2 children are alive. In the group of 99 patients that were treated surgical, 29 live. DFS--30%. CONCLUSIONS: 1. In case of osteosarcoma is profitable to extract metastatic focus in the period of stabilization after chemotherapy. 2. Also it seems purposely even many times excision of metastases. 3. Operation of metastatic focus makes it possible for patients to live many years. 28% of our patients live fifth years after the end of the treatment.


Bone Neoplasms/pathology , Bone Neoplasms/therapy , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Osteosarcoma/secondary , Osteosarcoma/therapy , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Bone Neoplasms/drug therapy , Bone Neoplasms/surgery , Chemotherapy, Adjuvant , Child , Child, Preschool , Disease-Free Survival , Female , Humans , Infant , Lung Neoplasms/drug therapy , Lung Neoplasms/surgery , Male , Osteosarcoma/drug therapy , Osteosarcoma/surgery , Poland , Prognosis , Retrospective Studies , Survival Analysis , Time Factors , Treatment Outcome
15.
Med Wieku Rozwoj ; 8(2 Pt 1): 235-43, 2004.
Article Pl | MEDLINE | ID: mdl-15738599

UNLABELLED: Among biochemical markers, which reflect bone remodeling and can be measured in blood, there are formation markers such as serum bone alkaline phosphatase (BALP) and osteocalcin (OC). Formation markers are considered to be useful in diagnosis and anticancer treatment of many metastatic bone diseases, but the clinical value of these markers in primary osseous tumours such as osteosarcoma is not yet recognized. AIM: The aim of this study was the investigation of BALP activity and OC level in patients with osteosarcoma during clinical treatment. SUBJECTS AND METHODS: We studied 22 patients (aged 11-19 years) with osteosarcoma, at diagnosis, during preoperative and postoperative chemotherapy and at the end of treatment. The control group consisted of 30 healthy age-matched children. The activity of BALP and the level of OC were measured in serum using ELISA kits. RESULTS: Our results indicated that both tested parameters were lower during preoperative and postoperative chemotherapy (BALP, p<0.05; OC, p<0.01,p<0.001), in patients group than in controls. However we found higher value of BALP and OC also at diagnosis and during chemotherapy in same patients before occurrence of metastases. Moreover, we observed markedly higher activity of BALP (5:fold) and level of OC (2-fold) in patients with progression in comparison to the group with favourable prognosis, who responded to chemotherapy. CONCLUSIONS: Our studies suggest, that investigation of formation markers, especially BALP could be useful in monitoring of osteosarcoma therapy and may be a valuable indicator of the progression of this disease. Further studies with long-term observation of investigated patients are necessary.


Alkaline Phosphatase/blood , Biomarkers, Tumor/blood , Bone Neoplasms/metabolism , Bone Regeneration , Osteocalcin/blood , Osteosarcoma/metabolism , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/blood , Bone Neoplasms/drug therapy , Bone Neoplasms/surgery , Bone Resorption , Case-Control Studies , Child , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Osteosarcoma/blood , Osteosarcoma/drug therapy , Osteosarcoma/surgery , Prognosis , Time Factors
...